This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOAbout ABRYSVOEfficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOResourcesResourcesMaternal RSV Vaccine PlannerHealth Plan CoverageRequest A RepEventsMaterialsVideos
Prescribing InformationIndications Older AdultPatient Site
What is RSV?RSV is a common virus that is particularly dangerous for infants1Icon of infected lungs

Transmitted from person to person via respiratory droplets2

Icon of baby coughing

RSV can infect the airways of an individual2

Hospital icon

Prevention is important. Treatment options are limited to supportive care2

 

Transmitted from person to person via respiratory droplets2

RSV can infect the airways of an individual2


Prevention is important. Treatment options are limited to supportive care2

Transmitted from person to person via respiratory droplets2

RSV can infect the airways of an individual2

Prevention is important. Treatment options are limited to supportive care2

RSV is the leading cause of hospitalizations in newborns1INFANTS UNDER 6 MONTHS OF AGE ARE AT THE HIGHEST RISK OF RSV HOSPITALIZATION1Cumulative data from 2016-2020: RSV-associated hospitalization rates in infants (0-6 months)3

There are ~80,000 RSV-associated infant hospitalizations each year in the US4*

Maternal immunization with ABRYSVO® is designed to protect infants from RSV immediately at birth through 6 months5,6

ABRYSVO is given during pregnancy

Pregnant woman receives ABRYSVO at 32 weeks and 0 days’ through 36 weeks and 6 days’ gestational age6,7

Maternal RSV antibodies are passed on

Pregnant woman’s immune system produces antibodies, which are passed through the placenta to the fetus6

Maternal RSV antibodies help protect the newborn

Infant is born with maternal antibodies, which help protect against RSV from birth through 6 months6

ReferencesThese data come from a meta-analysis where a rate per 1,000 was applied to the 2020 birth cohort of 4.1 million infants less than 1 year old.4

RSV=respiratory syncytial virus. Maternal RSV Vaccine Planner

For eligible patients, this tool estimates the ABRYSVO vaccination window based upon estimated pregnancy due date, season, and location, consistent with the approved ABRYSVO indication and CDC recommendation.

 View the Planner Loading Accessing ABRYSVO

Learn more about coverage for this RSV vaccine for eligible pregnant patients.

 Explore Now Loading Order ABRYSVO

Make ABRYSVO available to your pregnant patients by placing an order today.

 Order Now Loading View Resources

Discover helpful ABRYSVO resources and patient materials.

 Learn MoreLoading
Receive Updates About ABRYSVO Register NowLoading

Mon-Fri, 9 am – 5 pm ET

 Request a Pfizer Sales Representative Connect Now Loading Live Pfizer Connect Health and Science Representative

Mon-Fri, 9 am – 5 pm ET

 Call 1-844-966-5127 Loading Receive Updates About ABRYSVO Register NowLoading

Mon-Fri, 9 am – 5 pm ET

 Request a Pfizer Sales Representative Connect Now Loading Live Pfizer Connect Health and Science Representative

Mon-Fri, 9 am – 5 pm ET

 Call 1-844-966-5127 Loading

References:

Parikh RC, McLaurin KK, Margulis AV, et al. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017;6(4):477-486. doi:10.1007/s40121-017-0167-9Jain H, Schweitzer JW, Justice NA. Respiratory syncytial virus infection in children. Accessed December 1, 2023. https://www.ncbi.nlm.nih.gov/books/NBK459215/McMorrow M. Respiratory syncytial virus (RSV) seasonality in the United States and the burden of RSV in children. Presented at: Advisory Committee on Immunization Practices (ACIP) General Meeting; June 23, 2022; Atlanta, GA.McLaughlin JM, Khan F, Schmitt H-J, et al. Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis. J Infect Dis. 2022;225(6):1100-1111.Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464.ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; October 2024.Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1115-1122.
doi:10.15585/mmwr.mm7241e1

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-1727
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367
IndicationsABRYSVO is a vaccine indicated for:
 
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%) 
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO. IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV